Brokers Offer Predictions for NAMS FY2024 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at HC Wainwright issued their FY2024 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will post earnings per share of ($1.64) for the year. HC Wainwright currently has a “Buy” rating and a $48.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.

A number of other equities analysts have also weighed in on NAMS. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $38.17.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $25.70 on Wednesday. NewAmsterdam Pharma has a 12-month low of $11.18 and a 12-month high of $27.29. The firm has a 50 day moving average of $22.26 and a 200 day moving average of $19.26.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock valued at $5,485,000 after purchasing an additional 86,712 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after buying an additional 221,305 shares during the last quarter. abrdn plc boosted its stake in NewAmsterdam Pharma by 69.8% during the third quarter. abrdn plc now owns 129,060 shares of the company’s stock worth $2,142,000 after buying an additional 53,060 shares during the period. Millennium Management LLC increased its position in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after acquiring an additional 217,902 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of NewAmsterdam Pharma by 8.9% in the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after acquiring an additional 83,115 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now directly owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 416,884 shares of company stock worth $10,676,428 in the last 90 days. 19.50% of the stock is currently owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.